Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera, Inc. (Symbol: NTRA) is a leading diagnostic and research company based in San Carlos, CA, driven by a commitment to advance the science and application of prenatal testing. In the information age, medical diagnostics have lagged behind in adopting new technologies, but Natera is changing that narrative. The company specializes in preconception and prenatal genetic testing services, providing couples with crucial information throughout the pregnancy journey.
Natera offers a comprehensive range of tests, including Preimplantation Genetic Diagnosis (PGD) for IVF and Non-Invasive Prenatal Testing (NIPT). Their Panorama NIPT is particularly notable for its ability to screen for chromosomal abnormalities in a fetus, even in twin pregnancies, typically through a simple blood draw from the mother. Another significant product is the Horizon Carrier Screening (HCS), which determines carrier status for numerous severe genetic diseases that could be passed on to offspring.
The company's innovative approach leverages advances from the Human Genome Project and is powered by proprietary bioinformatics algorithms. This technology enables highly accurate genetic testing results. Natera's portfolio also includes the Signatera Molecular Residual Disease (MRD) Test, designed to detect circulating tumor DNA in cancer patients, helping to assess molecular residual disease and monitor recurrence. Additionally, the Prospera test assesses organ transplant rejection.
Through its pioneering genetic testing services and experienced genetic counseling, Natera provides valuable insights that help in informed decision-making for pregnancies and medical conditions. The company continues to make significant strides in the field of medical diagnostics, driven by a passion for innovation and excellence.
Natera, Inc. (Nasdaq: NTRA) announced the pricing of its underwritten public offering of 11,430,000 shares of common stock at $35.00 per share. The offering is expected to close on November 18, 2022, subject to customary conditions. Additionally, Natera has granted underwriters a 30-day option to purchase up to 1,714,500 additional shares. Morgan Stanley, Cowen, and SVB Securities are managing the offering, which is filed under an effective shelf registration statement with the SEC. This issuance aims to support Natera's ongoing operations in cell-free DNA testing for oncology and women's health.
Natera, Inc. (Nasdaq: NTRA), based in Austin, Texas, has announced a proposed follow-on public offering of $350 million in common stock. The offering may include an additional $52.5 million option for underwriters. The offering is subject to market conditions and no assurance can be made regarding its completion or terms. Morgan Stanley, Cowen, and SVB Securities are acting as joint book-running managers, with Baird as co-manager. The offering will be conducted under an effective shelf registration statement filed with the SEC.
Natera, Inc. (NASDAQ: NTRA) reported a strong third quarter for 2022, with total revenues of $210.6 million, up 33.2% from $158.1 million in Q3 2021. Product revenues rose 29.8% to $199.8 million. The company processed approximately 517,500 tests, an increase of 27.1%. Natera raised its revenue guidance for 2022 to $810 million - $830 million. Although net loss reduced from $151.3 million in Q3 2021 to $121.5 million, gross margin declined from 48.5% to 44.7% due to rising labor costs.
Natera, Inc. (NASDAQ: NTRA) has secured a nationwide contract with the U.S. Department of Veterans Affairs (VA) National Precision Oncology Program, effective September 15, 2022. This contract enables the provision of minimal residual disease (MRD) and monitoring services using the Signatera™ test, aimed at detecting cancer recurrence and informing treatment decisions. The VA serves over 450,000 veterans with cancer. Signatera™ is validated across multiple cancer types and is covered by Medicare for specific uses, enhancing its clinical utility and accessibility.
Natera, a leader in cell-free DNA testing, will participate in the Credit Suisse 31st Annual Healthcare Conference on November 9, 2022, at 10:25 a.m. PT. CEO Steve Chapman and CFO Mike Brophy will present at the event, highlighting Natera's advancements in personalized genetic testing. Interested parties can access the live webcast through the Natera Investor Relations website, where the presentation will also be archived for future reference.
Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA testing, will announce its third-quarter 2022 results on November 8, 2022, post-market. A conference call will follow at 1:30 p.m. PT (4:30 p.m. ET) to discuss financial outcomes, business activities, and future outlook. Investors can dial in at (888) 770-7321 for domestic or (929) 201-7107 for international access, using password 7684785. A webcast will also be available at this link. For more info on Natera, visit www.natera.com.
Natera, Inc. (NASDAQ: NTRA) announces a study published in Gynecologic Oncology, validating its molecular residual disease (MRD) test, Signatera, for epithelial ovarian cancer (EOC). The multi-site study of 163 plasma samples from 69 patients demonstrates that Signatera outperforms CA-125 in predicting recurrence. With 100% sensitivity and specificity, it detects recurrences an average of 10 months earlier than imaging. This advancement is crucial for ovarian cancer management, which has a high recurrence rate and poor survival rates.
Natera, Inc. (NASDAQ: NTRA) announced new findings from the Trifecta study, indicating that its Prospera Kidney test, which uses donor-derived cell-free DNA (dd-cfDNA), outperforms traditional donor-specific antibody (DSA) testing in predicting antibody-mediated rejection (AMR). The study assessed 280 samples, showing dd-cfDNA metrics had AUC values of 0.84 and 0.85, significantly higher than DSA's AUC of 0.66. The results advocate for broader dd-cfDNA use in kidney transplantation for more accurate graft status assessment.
Natera, Inc. (NASDAQ: NTRA) presented new data on its Signatera™ molecular residual disease (MRD) test at the ESMO World Congress in Paris from September 9-13, 2022. Key findings include results from a large real-world study with 16,347 colorectal cancer patients, indicating that MRD-positive status significantly correlates with poorer recurrence-free survival. Signatera’s application in monitoring response to immunotherapy in early stage triple-negative breast cancer was also highlighted. The data reinforces the clinical utility of personalized MRD testing in cancer treatment decision-making.
FAQ
What is the current stock price of Natera (NTRA)?
What is the market cap of Natera (NTRA)?
What does Natera, Inc. specialize in?
Where is Natera, Inc. headquartered?
What is the Panorama Non-Invasive Prenatal Test (NIPT)?
What is the Horizon Carrier Screening (HCS)?
What is the Signatera Molecular Residual Disease (MRD) Test?
What is the purpose of the Prospera test?
How has Natera advanced genetic testing?
Does Natera offer genetic counseling services?
What industries does Natera serve?
What makes Natera's tests unique?
